Figure 2.
CD33/CD123 NANOBODY TCE kills double- and single-target–expressing tumor cell lines. (A) Structural design of the CD33/CD123 NANOBODY TCE and control compounds. (B) Dose dependent T-cell–mediated MOLM-13; U-937 and KG-1a cell killing using an effector to target ratio of 10:1. The percentage of TO-PRO-3 positive target cells is plotted against the concentration of the CD33/CD123 NANOBODY TCE, CD33-CD3, CD123-CD3, or untargeted NANOBODY TCE. (C) CD33 and CD123 target receptor expression (number of receptors/cell): MOLM-13 (CD33: 32 448 antigens per cell; CD123: 6543); U-937 (CD33: 19 872; CD123: 945); and KG-1a (CD33: 800; CD123: 3353). One representative experiment is shown out of ≥4, global mean EC50s are shown in Table 2.

CD33/CD123 NANOBODY TCE kills double- and single-target–expressing tumor cell lines. (A) Structural design of the CD33/CD123 NANOBODY TCE and control compounds. (B) Dose dependent T-cell–mediated MOLM-13; U-937 and KG-1a cell killing using an effector to target ratio of 10:1. The percentage of TO-PRO-3 positive target cells is plotted against the concentration of the CD33/CD123 NANOBODY TCE, CD33-CD3, CD123-CD3, or untargeted NANOBODY TCE. (C) CD33 and CD123 target receptor expression (number of receptors/cell): MOLM-13 (CD33: 32 448 antigens per cell; CD123: 6543); U-937 (CD33: 19 872; CD123: 945); and KG-1a (CD33: 800; CD123: 3353). One representative experiment is shown out of ≥4, global mean EC50s are shown in Table 2.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal